36 46

Cited 0 times in

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer

Authors
 Alexander Drilon  ;  Geoffrey R Oxnard  ;  Daniel S W Tan  ;  Herbert H F Loong  ;  Melissa Johnson  ;  Justin Gainor  ;  Caroline E McCoach  ;  Oliver Gautschi  ;  Benjamin Besse  ;  Byoung C Cho  ;  Nir Peled  ;  Jared Weiss  ;  Yu-Jung Kim  ;  Yuichiro Ohe  ;  Makoto Nishio  ;  Keunchil Park  ;  Jyoti Patel  ;  Takashi Seto  ;  Tomohiro Sakamoto  ;  Ezra Rosen  ;  Manisha H Shah  ;  Fabrice Barlesi  ;  Philippe A Cassier  ;  Lyudmila Bazhenova  ;  Filippo De Braud  ;  Elena Garralda  ;  Vamsidhar Velcheti  ;  Miyako Satouchi  ;  Kadoaki Ohashi  ;  Nathan A Pennell  ;  Karen L Reckamp  ;  Grace K Dy  ;  Jürgen Wolf  ;  Benjamin Solomon  ;  Gerald Falchook  ;  Kevin Ebata  ;  Michele Nguyen  ;  Binoj Nair  ;  Edward Y Zhu  ;  Luxi Yang  ;  Xin Huang  ;  Elizabeth Olek  ;  S Michael Rothenberg  ;  Koichi Goto  ;  Vivek Subbiah 
Citation
 NEW ENGLAND JOURNAL OF MEDICINE, Vol.383(9) : 813-824, 2020-08 
Journal Title
NEW ENGLAND JOURNAL OF MEDICINE
ISSN
 0028-4793 
Issue Date
2020-08
MeSH
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung / drug therapy* ; Female ; Humans ; Hypertension / chemically induced ; Intention to Treat Analysis ; Lung Neoplasms / drug therapy* ; Male ; Middle Aged ; Mutation ; Progression-Free Survival ; Protein Kinase Inhibitors / administration & dosage* ; Protein Kinase Inhibitors / adverse effects ; Proto-Oncogene Proteins c-ret / analysis ; Proto-Oncogene Proteins c-ret / antagonists & inhibitors* ; Proto-Oncogene Proteins c-ret / genetics ; Pyrazoles / administration & dosage* ; Pyrazoles / adverse effects ; Pyridines / administration & dosage* ; Pyridines / adverse effects ; Transaminases / blood ; Treatment Outcome ; Young Adult
Abstract
Background: RET fusions are oncogenic drivers in 1 to 2% of non-small-cell lung cancers (NSCLCs). In patients with RET fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.

Methods: We enrolled patients with advanced RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated separately in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response) as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety.

Results: In the first 105 consecutively enrolled patients with RET fusion-positive NSCLC who had previously received at least platinum-based chemotherapy, the percentage with an objective response was 64% (95% confidence interval [CI], 54 to 73). The median duration of response was 17.5 months (95% CI, 12.0 to could not be evaluated), and 63% of the responses were ongoing at a median follow-up of 12.1 months. Among 39 previously untreated patients, the percentage with an objective response was 85% (95% CI, 70 to 94), and 90% of the responses were ongoing at 6 months. Among 11 patients with measurable central nervous system metastasis at enrollment, the percentage with an objective intracranial response was 91% (95% CI, 59 to 100). The most common adverse events of grade 3 or higher were hypertension (in 14% of the patients), an increased alanine aminotransferase level (in 12%), an increased aspartate aminotransferase level (in 10%), hyponatremia (in 6%), and lymphopenia (in 6%). A total of 12 of 531 patients (2%) discontinued selpercatinib because of a drug-related adverse event.

Conclusions: Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.).
Files in This Item:
T202007215.pdf Download
DOI
10.1056/NEJMoa2005653
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/183899
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links